MARKET

CRIS

CRIS

Curis
NASDAQ
0.5555
-0.0245
-4.22%
Closed 19:18 03/27 EDT
OPEN
0.5836
PREV CLOSE
0.5800
HIGH
0.6300
LOW
0.5230
VOLUME
465.60K
TURNOVER
0
52 WEEK HIGH
3.130
52 WEEK LOW
0.5230
MARKET CAP
22.21M
P/E (TTM)
-0.9644
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CRIS last week (0323-0327)?
Weekly Report · 8h ago
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—3/26/26
TipRanks · 4d ago
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—3/25/26
TipRanks · 5d ago
VTI Sees $2B in Net Flows – Why Investors Are Pouring Into This Vanguard ETF
TipRanks · 6d ago
Why Is Vanguard Total Stock Market ETF (VTI) Up Today, 03/23/26?
TipRanks · 03/23 14:33
Analysts Are Bullish on Top Healthcare Stocks: Curis (CRIS), Maze Therapeutics, Inc. (MAZE)
TipRanks · 03/23 12:20
Analysts Offer Insights on Healthcare Companies: Curis (CRIS), Spyre Therapeutics (SYRE) and Prothena (PRTA)
TipRanks · 03/23 12:01
Weekly Report: what happened at CRIS last week (0316-0320)?
Weekly Report · 03/23 09:53
More
About CRIS
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.

Webull offers Curis Inc stock information, including NASDAQ: CRIS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRIS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRIS stock methods without spending real money on the virtual paper trading platform.